Marrone Bio Innovations (MBII) Stock Price, News & Analysis

Company Overview

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

Key Stats

• Today's Range: $0.80 to $0.80
• 50-Day Range: $0.80 to $0.80
• 52-Week Range: $0.55 to $1.55
• Volume: 38 shs
• Average Volume: 919,497 shs
• Market Capitalization: $145.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MBII Stock Analysis - Frequently Asked Questions

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations, Inc. (NASDAQ:MBII) issued its earnings results on Wednesday, November, 10th. The basic materials company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The basic materials company had revenue of $9.86 million for the quarter, compared to analysts' expectations of $10.79 million. Marrone Bio Innovations had a negative trailing twelve-month return on equity of 70.87% and a negative net margin of 47.07%.
Read the conference call transcript.

What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Marrone Bio Innovations investors own include ObsEva (OBSV), Amyris (AMRS), Avino Silver & Gold Mines (ASM), Rexahn Pharmaceuticals (REXN), Plug Power (PLUG), Denali Therapeutics (DNLI) and

Company Calendar

• Last Earnings: 11/10/2021
• Today: 8/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Basic Materials
• Industry: Agricultural Chemicals
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MBII
• CIK: 1441693
• Web: www.marronebioinnovations.com
• Phone: (530) 750-2800
• Fax: N/A
• Employees: 153
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.55 million
• Net Margins: -47.07%
• Pretax Margin: -47.12%
• Return on Equity: -70.87%
• Return on Assets: -25.23%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 0.79
• Quick Ratio: 0.55

Sales & Book Value

• Annual Sales: $44.31 million
• Price / Sales: 3.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 4.69

Miscellaneous

• Outstanding Shares: 182,378,000
• Free Float: 173,259,000
• Market Cap: $145.56 million
• Optionable: Not Optionable
• Beta: 0.36